Nevertheless, recent data suggest that relapse risk is higher in patients with FLT3-ITD AML irrespective of AR or presence of NPM1 mutation, and these patients should be considered for alloHSCT in first remission (CR1) if eligible [109, 110]; this is reflected in the updated ELN recommendations [24]. This evidence concerns the gene FLT3 and acute myeloid leukemia.